Familial Systemic Scleroderma

Studying familial forms of systemic scleroderma offers several advantages: 1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.

NCT Number	NCT07343115
Lead Sponsor	University Hospital, Strasbourg, France
Conditions	Systemic Scleroderma
Enrollment	20 participants
Start Date	2025-09-02
Primary Completion	2026-09 (estimated)
Study Completion	2026-09-02 (estimated)
Updated on ClinicalTrials.gov	2026-01-15